UBS analyst Eliana Merle lowered the price target on Rapt Therapeutics (NASDAQ: RAPT) to $1.00 (from $2.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE